This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
The company is bringing precision therapies for gynaecological cancers
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Subscribe To Our Newsletter & Stay Updated
